InnovAge (INNV) Q3 2026 earnings review
Core Operations Accelerate, Sidelined by $52M Litigation Charge
InnovAge delivered an operationally stellar third quarter, with revenue accelerating to 15.5% YoY growth and Center-Level Contribution Margin expanding 550 basis points to 24.2%. Core profitability is undeniably scaling, prompting management to raise full-year Revenue and Adjusted EBITDA guidance. However, this operational success was entirely wiped out on a GAAP basis by a massive $51.9M litigation and settlement charge, reversing the recent return to profitability and pushing Net Income to a $29.9M loss. While the underlying PACE model is demonstrating powerful operating leverage, investors must weigh accelerating fundamentals against the severe cost of legacy legal cleanup.
🐂 Bull Case
Adjusted EBITDA more than doubled YoY to $30.5M, expanding the margin to 12.1% from 4.9%. This proves that the multi-year foundational rebuild and clinical value initiatives are generating sustainable operating leverage.
Management confidently raised FY26 Adjusted EBITDA guidance from $70-$75M to $85-$90M. The company is generating enough operational momentum to significantly outperform its initial yearly targets.
🐻 Bear Case
The $51.9M litigation and settlement charge recorded in Q3 destroys the narrative of a clean turnaround. Continual one-off legal costs mask the underlying operational progress.
Quarter-over-quarter participant growth decelerated sharply, adding only 40 net participants in Q3 vs 120 in Q2. Reaffirming the FY26 census guide of 7,900-8,100 implies zero growth or net contraction in Q4.
⚖️ Verdict: ⚪
Neutral. The discrepancy between the booming Adjusted EBITDA and the collapsing GAAP Net Income is stark. Operations are thriving, but legacy liabilities are a heavy anchor.
Key Themes
Center-Level Margins Showing Powerful Acceleration
Center-Level Contribution Margin expanded dramatically to 24.2%, up from 18.7% a year ago and 22.0% in Q2. This demonstrates accelerating returns from the company's Clinical Value Initiatives (CVIs) aimed at controlling inpatient and skilled nursing facility (SNF) utilization, coupled with the continued integration of in-house pharmacy services.
Massive Litigation Charge Eclipses Turnaround
Reversing its recent streak of positive net income, InnovAge reported a massive $51.9M expense for litigation and settlements in Q3. This is a dramatic escalation compared to the $1.3M charge in Q2 and $13.3M in the prior-year period. While classified as a non-recurring add-back for Adjusted EBITDA, these severe cash obligations contradict the 'clean execution' narrative presented by management.
Census Growth is Decelerating
Ending census grew to 8,050 in Q3, up from 8,010 in Q2, representing a sequential deceleration in net participant additions. Furthermore, maintaining the FY26 guidance range of 7,900 to 8,100 participants implies that management expects flat to negative net enrollment in Q4. This reflects ongoing headwinds from state Medicaid redeterminations and proactive disenrollment of ineligible members.
Revenue Integrity Work Yielding Top-Line Growth
Total revenue grew an impressive 15.5% YoY to $251.9M. This accelerating growth highlights success in improving internal revenue integrity processes, better management of Medicaid eligibility, and favorable rate environments, which were flagged as core operational priorities in previous quarters.
Technology Integration Improving Execution
InnovAge's continued integration of modern technological platforms, including Epic EMR for clinical workflows and Salesforce for revenue reserves, is reducing unwarranted variance in care ordering and administrative overhead. This innovation directly supports the improved center-level margins and SG&A leverage seen this quarter.
Macro Pressures: The V28 Transition and State Budgets
Despite operational outperformance, macro concerns remain. The upcoming CMS phase-in of the V28 Medicare risk model (starting 2026) places persistent pressure on risk scores. Concurrently, ongoing state-level Medicaid budgetary strain introduces risk to future capitation rate increases.
Other KPIs
Decelerating core efficiency masked by litigation. While reported CG&A almost doubled YoY ($38.6M to $76.5M), $51.9M of this was the litigation settlement. Stripping out the legal charge, core CG&A expenses are actually tracking lower than the prior year, demonstrating leverage from the recent 'spans and layers' organizational restructuring.
Stable liquidity profile. Total cash and equivalents ($95.5M) plus short-term investments ($43.1M) remain robust and represent an increase from the $105.9M combined position at the end of FY25. The company maintains adequate liquidity to absorb the elevated legal settlement costs while managing $69.4M in total debt.
Guidance
Accelerating. Management raised the full-year target from the previous $925-$950M range. Given the $727.7M generated in the first three quarters, hitting the midpoint ($962.5M) implies Q4 revenue of approximately $234.8M, factoring in seasonal fluctuations.
Accelerating. Raised significantly from the previous $70-$75M target. The new midpoint ($87.5M) requires approximately $17.2M in Q4 Adjusted EBITDA, an achievable goal considering the company has already generated $70.3M through the first three quarters.
Stable. The guidance was left unchanged despite Q3 ending at 8,050. This confirms management's earlier caution that rapid, proactive disenrollment of ineligible Medicaid members will suppress net top-line member growth in the short term.
Key Questions
Clarity on the $51.9M Litigation Charge
The $51.9M litigation and settlement charge effectively erased Q3's operational successes on the bottom line. Is this the final resolution to the legacy stockholder and pharmacy provider disputes, or should investors anticipate further trailing legal costs?
Q4 Census Implications
Ending Q3 at 8,050 participants means you are already near the top end of the reaffirmed 7,900-8,100 guidance range. Does this explicitly imply you anticipate negative net enrollment in Q4, and if so, is this entirely driven by state redeterminations?
Margin Sustainability
Center-Level Contribution Margin reached an impressive 24.2%. As de novo centers continue to scale and the in-house pharmacy matures, is a 24%+ run-rate the new normal, or were there seasonal/one-time acuity benefits in Q3?